Potter M E, Partridge E E, Shingleton H M, Soong S J, Kim R Y, Hatch K D, Austin J M
University of Alabama, Department of Obstetrics and Gynecology, Birmingham 35294.
Gynecol Oncol. 1989 Mar;32(3):314-8. doi: 10.1016/0090-8258(89)90631-8.
Between March 1977 and December 1985, 59 patients were treated with intraperitoneal chromic phosphate at The University of Alabama Birmingham Hospitals and its affiliates. Twenty-seven patients received primary adjuvant therapy. Thirty-two patients were treated "secondarily" after tumor recurrence or after a "positive" second-look laparotomy. Associated morbidity was noted to be 12% with reoperation required in 7%. Early stage and grade tumors demonstrate a good prognosis. Little, if any, benefit was demonstrated in "secondary" therapy of advanced stage and grade tumors.
